Remove 2021 Remove FDA Remove Immunization
article thumbnail

Budget 2021: Sunak focuses on vaccine development to restart economy

pharmaphorum

Instead of large phase 3 trials, the MHRA will require studies showing immune responses for tweaked versions of previously approved vaccines, in line with similar guidance issued by the FDA late last month. The post Budget 2021: Sunak focuses on vaccine development to restart economy appeared first on.

Vaccines 105
article thumbnail

Immunocore claims first-ever FDA approval for TCR cancer therapy

pharmaphorum

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The post Immunocore claims first-ever FDA approval for TCR cancer therapy appeared first on.

FDA 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ampio slumps as FDA delivers knee osteoarthritis shock

pharmaphorum

Ampio Pharma’s candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review. The FDA said it should have been advised of the proposed changes before Ampio unblinded and analysed the data from the AP-013 study.

FDA 111
article thumbnail

4 vitamins for post-COVID fatigue

The Checkup by Singlecare

Vitamin D Vitamin D coupons Most people think of vitamin D as the sunshine vitamin without realizing how big of an impact it has on our immune system. Low levels of vitamin D have been linked to poor immune function and fatigue, which can inhibit your recovery from COVID, says Simpson. Who should avoid vitamins for post-COVID fatigue?

article thumbnail

Study: Biosimilarities Found Between Yusimry and Humira for Immune, Rheumatic Conditions

Pharmacy Times

Adalimumab-aqvh (Yusimry; Coherus Biosciences) entered the market in July 2023, following approval by the FDA in December 2021.

article thumbnail

EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejection

pharmaphorum

Sanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) were dashed by the FDA, but new phase 3 data keep the drugmaker on track for a resubmission before year-end. Sutimlimab, which Sanofi acquired via its $11.6

FDA 93
article thumbnail

New Legislation Would Cut Off Access To The Courts And Immunize FDA Actions From Timely Judicial Review

The FDA Law Blog

Senate Committee on Health, Education, Labor and Pensions (“Senate HELP”) is scheduled to take up legislation that could significantly limit access to the courts and immunize critical FDA decisions from timely judicial review. Subsection 505(q) initially was added by Section 914 of the 2007 FDA Amendments Act (“FDAAA”), Pub.